Filing Flows › Roivant Sciences (ROIV) › Q4 FY25
Roivant Sciences (ROIV) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed May 29, 2025
Roivant Sciences (ROIV) reported revenue of $7.6M for the fourth quarter fiscal 2025 (Q4 FY25), -16% from a year earlier and -16% from the quarter before.
Roivant Sciences, Q4 FY25: revenue $7.6M (-16% year over year), net loss $252M, operating cash flow −$173M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.6M | -16% | -16% |
| Operating profit | −$285M | — | — |
| Net earnings | −$252M | -314% | — |
| Operating cash flow | −$173M | — | — |
What changed
Revenue was $7.6M in Q4 FY25, down 16% year over year and down 16% from the previous quarter.
Operating costs exceeded revenue by $285.0M, an operating margin of -3764.4%. Total costs grew 36% against a revenue fall of 16%. The quarter ended with a net loss of $252.4M, after a profit of $118.1M the previous quarter. Minority interests bore $45.9M of it: to shareholders the quarter was a loss of $206.5M. Non-operating items added $81.9M, -40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$172.6M. Non-cash charges added back $1.4M of depreciation and amortization and $83.5M of share-based compensation. Capital expenditures of $811K exceeded it, leaving free cash flow of −$173.4M.
Questions
What was Roivant Sciences' revenue in the fourth quarter fiscal 2025?
Roivant Sciences (ROIV) reported revenue of $7.6M for the fourth quarter fiscal 2025 (Q4 FY25), -16% from a year earlier and -16% from the quarter before.
Source: Roivant Sciences 10-K on SEC EDGAR.